All News
Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain intensity was associated with working life impairment, spinal stiffness, education, gender, depression, anxiety and sleep @RheumNow, #ACR21 and Abst#0360 https://t.co/xEVI4L0Chw
Dr. Antoni Chan synovialjoints ( View Tweet)
There remains a need to increase knowledge and awareness of #axialspondyloarthritis in this US study of nearly 200 primary care physicians, less than half of the time were IBP symptoms, psoriasis, HLA-B27, CRP or MRI checked @RheumNow, #ACR21 Abst#0370
https://t.co/6Uyy45OEYZ
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2
Olga Petryna DrPetryna ( View Tweet)
Abst0357 #acr2021 @rheumnow Irish registry concludes higher level of unemployment in axSpA pts associated w/high disease activity, poor quality of life & worse spinal mobility https://t.co/GsGPLOoWsk
Olga Petryna DrPetryna ( View Tweet)
Abst0369 #acr2021 @rheumnow #acrbest ⬆️ level of pregnancy complications in axSpA in Irish registry. 41.9% complicated, 11.4% pregnan w/multiple complications. Miscarriage 20.5%. Amongst live births 10.8% c-section, preterm 11.4% . NICU admiss11.4%. ⬇️ breastfeeding rate at 33.7% https://t.co/plF8fykCKT
Olga Petryna DrPetryna ( View Tweet)
Abst0909 #ACR21 @RheumNow #acrbest real life study pinpoints higher disease burden, severity of depressed mood & higher Mean ASAS-HI in F pts w/AS. secukinumab improved disease activity, global functioning and severity of depressive mood in AS patients in both men and women https://t.co/fQycXY1aed
Olga Petryna DrPetryna ( View Tweet)
Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy.
Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions.
What would you choose?
#ACR21
#ACRBest
@RheumNow https://t.co/FywUp3zCj2
Robert B Chao, MD doctorRBC ( View Tweet)
Differences in secukinumab pain response in AxSpA pts based on HLA-B27 sub-types.
Homozygous group = more uveitis, arthritis, enthesitis, male
Abs#917
#ACR21 @RheumNow
https://t.co/3TL9PdS4xx https://t.co/QQ0Tdye1Z9
Robert B Chao, MD doctorRBC ( View Tweet)
EDUCATE! 📣EMPOWER!📣
Prof FMiller shares adaptive measures against predicted impacts of #climate change on rheumatic diseases.
📍We all have a role to play in this.
@RheumNow #ACR21 #MedTwitter #RheumTwitter https://t.co/asJcnm104k
sheila RHEUMarampa ( View Tweet)
An important slide showing how UV radiation affects #Immunity
🔅suppress APCs
🔅promotes #cytokine production
🔅inhibits cytotoxic & memory T cells
🔅⬆ monocyte recruitment 👉⬆ IFN
🔸⬆UV exposure, ⬆ risk of dev't/flares of #lupus, DM
@RheumNow #ACR21 #climatechange https://t.co/e9glxfy6wR
sheila RHEUMarampa ( View Tweet)
Interim analysis of AURORA 2 Extension study:
🦋Voclosporin maintained meaningful reductions in UPCR and eGFR remained stable until month 30.
🦋No unexpected new AEs
Promising results!
@RheumNow #ACR21 #ACRBest abs1425 https://t.co/hBB6k0bDYb
sheila RHEUMarampa ( View Tweet)
Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes, ( @RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/Q50kEr5WEU https://t.co/5DScK5krtw
Links:
Dr. John Cush RheumNow ( View Tweet)
CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY
Dr. Rachel Tate uptoTate ( View Tweet)
AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting.
https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr1457 Nine more well-phenotyped patients with VEXAS were presented. New info:
💠Peritubular capillaritis & cryo vasculitis
💠Most cs- & bDMARDs had limited efficacy
💠Potential therapy with plasma cell blockade & stem cell transplant
@RheumNow https://t.co/iDwJAdbf4M https://t.co/X4ENz4M91u
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24.
Reassuring data.
@RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
sheila RHEUMarampa ( View Tweet)
Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC )
#ACR21
https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG
Links:
Dr. John Cush RheumNow ( View Tweet)
Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr
Janet Pope Janetbirdope ( View Tweet)
Interesting question came up: why would you change a RA patient from JAKi to JAKi?
The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way).
That would clearly favour to better survival
#ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit
David Liew drdavidliew ( View Tweet)
#ACR21 #Abstr1484 Hands down one of the most impressive results and trial design. RHAPSODY: Rilonacept led to ⬇️risk of pericarditis recurrence vs PBO (7% vs 74%; HR 0.04). Median time to resolution of pain and CRP were 5 & 7 Days. FDA approved @RheumNow https://t.co/Zty2WnkJEQ https://t.co/xGqt9Lwvjj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)